Recombinant zoster vaccine (Shingrix<sup>®</sup>): a new option for the prevention of herpes zoster and postherpetic neuralgia
Grisuna Singh, Se-Jin Song, Eun Joo Choi, Pyung Bok Lee, Francis Sahngun Nahm
Abstract
). This RZV has shown promising results in many clinical trials, with high reactogenicity and similar systemic adverse effects compared to those of LZV. The National Advisory Committee on Immunization has recommended LZV as a standard vaccine for HZ prevention in adults ≥ 50 years of age, but no studies directly comparing the safety and efficacy of RZV and LZV vaccines have been conducted. This article reviews the brief history, efficacy, and safety of the two vaccines and discusses the advantage of RZV over LZV based on the available literature.
Topics & Concepts
Postherpetic neuralgiaReactogenicityMedicineAdverse effectVaccinationImmunizationClinical trialPediatricsVirologyNeuropathic painImmunologyInternal medicinePharmacologyAntigenHerpesvirus Infections and TreatmentsRabies epidemiology and controlHealthcare and Venom Research